Paul Gordon

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Advances in clinical trials for amyotrophic lateral sclerosis
    Paul H Gordon
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 5:48-54. 2005
  2. ncbi Outcome measures for early phase clinical trials
    Paul H Gordon
    Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:270-3. 2007
  3. ncbi Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007
  4. ncbi A screening assessment of cognitive impairment in patients with ALS
    Paul H Gordon
    Departmen of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 8:362-5. 2007
  5. ncbi Randomized controlled phase II trial of glatiramer acetate in ALS
    P H Gordon
    Department of Neurology, Columbia University, NY, USA
    Neurology 66:1117-9. 2006
  6. ncbi The natural history of primary lateral sclerosis
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 66:647-53. 2006
  7. doi A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
  8. doi Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 72:1948-52. 2009
  9. doi Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center and New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 360:1946-59. 2009
  10. doi Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery L
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 119:680-6. 2009

Research Grants

Detail Information

Publications44

  1. ncbi Advances in clinical trials for amyotrophic lateral sclerosis
    Paul H Gordon
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, 9th Floor, 710 West 168th Street, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 5:48-54. 2005
    ..This article is devoted to the recent evolution of clinical trials in ALS and discusses specific trials conducted during the past 5 years...
  2. ncbi Outcome measures for early phase clinical trials
    Paul H Gordon
    Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:270-3. 2007
    ..The ALSFRS-R most strongly predicted survival and provided the most complete data, but large changes may be necessary before patients perceive treatment effects...
  3. ncbi Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    Paul H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Lancet Neurol 6:1045-53. 2007
    ..Several trials are planned or are in progress to assess whether minocycline slows human neurodegeneration. We aimed to test the efficacy of minocycline as a treatment for amyotrophic lateral sclerosis (ALS)...
  4. ncbi A screening assessment of cognitive impairment in patients with ALS
    Paul H Gordon
    Departmen of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 8:362-5. 2007
    ..Behavioral and motor impairment is associated with depressive symptoms in caregivers. Studies with formal neuropsychological tests are needed to determine the sensitivity and specificity of the screen in ALS...
  5. ncbi Randomized controlled phase II trial of glatiramer acetate in ALS
    P H Gordon
    Department of Neurology, Columbia University, NY, USA
    Neurology 66:1117-9. 2006
    ..01). Treated patients showed enhanced lymphocyte proliferation (p = 0.02). The safety profile and immune effects support conducting larger trials of dose selection and efficacy...
  6. ncbi The natural history of primary lateral sclerosis
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 66:647-53. 2006
    ....
  7. doi A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
  8. doi Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS
    P H Gordon
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 72:1948-52. 2009
    ..To determine how clinical features at the first evaluation and in follow-up can be used to suggest a diagnostic outcome for patients with only upper motor neuron (UMN) signs at disease onset...
  9. doi Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction
    Gregg W Stone
    Columbia University Medical Center and New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 360:1946-59. 2009
    ....
  10. doi Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery L
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, 111 E 59th St, 11th Floor, New York, NY 10022, USA
    Circulation 119:680-6. 2009
    ..The safety and efficacy of EES after 1 year have not been reported...
  11. doi Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
    Roxana Mehran
    Columbia University Medical Center New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA
    Lancet 374:1149-59. 2009
    ..Here, we assess whether these initial benefits were maintained at 1 year of follow-up...
  12. ncbi Quantitative objective markers for upper and lower motor neuron dysfunction in ALS
    H Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Neurology 68:1402-10. 2007
    ..To investigate the value of objective biomarkers for upper (UMN) and lower (LMN) motor neuron involvement in ALS...
  13. ncbi Development and evaluation of a self-administered version of the ALSFRS-R
    J Montes
    Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032
    Neurology 67:1294-6. 2006
    ..The self-administered ALSFRS-R showed excellent reliability (intraclass correlation = 0.93, 95% CI: 088 to 0.96) and similar sensitivity to change over time vs the standard evaluator-administered ALSFRS-R...
  14. ncbi Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis
    P H Gordon
    Department of Neurology, Columbia University, New York, USA
    Neurology 62:1845-7. 2004
    ..057), and blood urea nitrogen and liver enzymes became elevated (p < 0.05). Using these data, the authors have designed and launched a phase III trial...
  15. doi Prevalence of fatigue and depression in ALS patients and change over time
    M C McElhiney
    New York State Psychiatric Institute, Unit 51, New York, NY 10032, USA
    J Neurol Neurosurg Psychiatry 80:1146-9. 2009
    ..Amyotrophic lateral sclerosis (ALS) patients report both fatigue and depression. It is not clear how frequently each occurs, to what extent they occur together, how each relates to ALS disease status, or their stability over time...
  16. pmc Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
    Petra Kaufmann
    Department of Neurology, Clinical Coordinating Center, Columbia University, New York, NY 10032, USA
    Ann Neurol 66:235-44. 2009
    ..Our aims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in a Phase III clinical trial...
  17. ncbi The ALSFRSr predicts survival time in an ALS clinic population
    P Kaufmann
    Department of Neurology, College of Physicians and Surgeons, The Neurologic Institute, Columbia University, 710 W 168th Street, New York, NY 10032, USA
    Neurology 64:38-43. 2005
    ..To determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRSr), a predictor of survival time in ALS clinical trials, predicts survival time in an ALS clinic population...
  18. ncbi Identification of a novel D109Y mutation in Cu/Zn superoxide dismutase (sod1) gene associated with amyotrophic lateral sclerosis
    Ali Naini
    H Houston Merritt Center, Department of Neurology, Columbia University Medical Center, New York, NY 10032, USA
    J Neurol Sci 254:17-21. 2007
    ..This amino acid change in the protein however, did not alter the catalytic activity of the SOD1 enzyme as there was no change in the enzymatic activity of purified SOD1 from the patient's erythrocytes compared to control...
  19. doi Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
    Adriano Caixeta
    Columbia University Medical Center and the Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA
    JACC Cardiovasc Interv 3:1220-8. 2010
    ..The purpose of this study was to investigate long-term 3-year clinical outcomes of an everolimus-eluting stent (EES) versus a paclitaxel-eluting stent (PES)...
  20. ncbi Randomized control trials in ALS: lessons learned
    Hiroshi Mitsumoto
    The Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:8-13. 2004
  21. ncbi Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial
    Amir Halkin
    Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 150:1163-70. 2005
    ..We sought to evaluate the impact of baseline RI on clinical and angiographic outcomes in patients undergoing elective percutaneous coronary intervention using either bare metal or paclitaxel-eluting stents...
  22. doi Web-based data management for a phase II clinical trial in ALS
    Richard Buchsbaum
    Department of Biostatistics, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
    Amyotroph Lateral Scler 10:374-7. 2009
    ..Given sufficient resources, a comprehensive web-based data management system can meet the need for clean, available data in clinical trials in ALS and similar diseases, and can contribute significantly to their efficient execution...
  23. ncbi Early electrodiagnostic findings in Guillain-Barré syndrome
    P H Gordon
    Department of Neurology, University of New Mexico School of Medicine, 915 Camino de Salud NE, Albuquerque, NM 87131, USA
    Arch Neurol 58:913-7. 2001
    ..Although nerve conduction studies are a diagnostic aid, the characteristic electrical changes may not evolve for several weeks. Early diagnosis of GBS is important, however, because early treatment has been shown to improve outcome...
  24. ncbi Neuroleptic malignant syndrome in advanced Parkinson's disease
    P H Gordon
    Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York, USA
    Mov Disord 16:960-2. 2001
    ..His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa...
  25. doi Oxidative stress biomarkers in sporadic ALS
    Hiroshi Mitsumoto
    Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University Medical Center, New York, NY 10032, USA
    Amyotroph Lateral Scler 9:177-83. 2008
    ..ELISA may be reliable and thus useful in epidemiology studies requiring large numbers of samples to determine the significance of increased oxidative stress markers in SALS. Further studies are required...
  26. ncbi Amyotrophic lateral sclerosis
    Paul H Gordon
    Eleanor and Lou Gehrig Muscular Dystrophy Association Amyotrophic Lateral Sclerosis Research Center, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Sci Aging Knowledge Environ 2003:dn2. 2003
    ..Cognition, the extraocular muscles, and the urinary sphincters were spared. Respiratory muscle weakness was a late manifestation...
  27. ncbi Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial
    Petra Kaufmann
    Department of Neurology, The Eleanor and Lou Gehrig MDA ALS Research Center, College of Physicians and Surgeons, New York, NY, USA
    Amyotroph Lateral Scler 8:42-6. 2007
    ..97 (95% CI 0.93-0.98). We conclude that the ALSFRS-R shows excellent inter- and intra-rater reliability, and reliability of telephone administration when used as primary outcome measure in a multicenter ALS trial...
  28. ncbi ALSFRS-R
    Paul H Gordon
    Eleanor and Lou Gehrig MDA ALS Research Center, Neurological Institute, New York, NY 10032, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:90-3. 2004
    ..Unlike the other standard outcome measures currently employed, the ALSFRS-R is also a measure of global function...
  29. ncbi An observational study of cognitive impairment in amyotrophic lateral sclerosis
    Gregory A Rippon
    Department of Neurology, Gertrude H Sergievsky Center, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Eleanor and Lou Gehrig MDA ALS Research Center, New York, NY, USA
    Arch Neurol 63:345-52. 2006
    ..Clinical and pathologic features overlap in frontotemporal lobar dementia and ALS. Demographics, respiratory status, bulbar site of onset, and disease severity are potential risk factors for cognitive impairment in ALS...
  30. doi Amyotrophic lateral sclerosis with ragged-red fibers
    Michio Hirano
    Department of Neurology, Columbia University Medical Center, 3 317 Russ Berrie Medical Science Pavilion, 1150 St Nicholas Ave, New York, NY 10032, USA
    Arch Neurol 65:403-6. 2008
    ..Motor neuron diseases (amyotrophic lateral sclerosis [ALS] and spinal muscular atrophy [SMA]) have been rarely associated with mitochondrial respiratory chain defects...
  31. ncbi Selecting promising ALS therapies in clinical trials
    Ying Kuen Cheung
    Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, USA
    Neurology 67:1748-51. 2006
    ....
  32. ncbi Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
    Paul H Gordon
    Neurology 67:1314-5; author reply 1314-5. 2006
  33. ncbi Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients
    R Lee Mosley
    Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198 5800, USA
    Amyotroph Lateral Scler 8:235-42. 2007
    ..These data show significant humoral responses and cytokine trends following GA immunization in ALS patients...
  34. ncbi Minocycline-induced skin and dental pigmentations
    Tahseen Mozaffar
    Department of Neurology, University of California, Irvine, 101 The City Drive South, Bldg 22 C, Route 13, Orange, CA 92868, USA
    Neurology 67:2185. 2006
  35. ncbi The Timed Up and Go test: predicting falls in ALS
    Jacqueline Montes
    Department of Neurology, College of Physicians and Surgeons, The Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:292-5. 2007
    ..The TUG test can guide management of patients with ALS; a time of 14 s can be used to prompt the recommendation for mobility aids to prevent falls...
  36. ncbi Extensor digitorum brevis test and resistance to botulinum toxin type A
    Paul H Gordon
    Department of Neurology, ACC 2, University of New Mexico, 915 Camino de Salud NE, Albuquerque, New Mexico 87131, USA
    Muscle Nerve 26:828-31. 2002
    ..Four of five resistant patients had values outside the normal range. The EDB test is a simple quantitative method of detecting resistance to BTX-A, with a sensitivity of 80% and specificity of 94%...
  37. ncbi Current clinical trials in amyotrophic lateral sclerosis
    Jaydeep M Bhatt
    Columbia University, Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Neurological Institute, New York, NY 10032, USA
    Expert Opin Investig Drugs 16:1197-207. 2007
    ..There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design...
  38. ncbi Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexes
    Paul H Gordon
    Department of Neurology, Division of Movement Disorders, Columbia Presbyterian Medical Center, New York, New York 10032, USA
    Mov Disord 19:950-61. 2004
    ..A woman who had her first serious fall at age 48 years subsequently developed neurological symptoms. Her case is described, differential diagnoses are presented, pathology is discussed, and a final diagnosis is reached...
  39. pmc Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery
    Katrina Gwinn
    National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 2:e1254. 2007
    ..This resource should facilitate genetic discoveries which we anticipate will ultimately provide a better understanding of the biological mechanisms of neurodegeneration in ALS...
  40. ncbi Reaction time and movement time after embryonic cell implantation in Parkinson disease
    Paul H Gordon
    Department of Neurology and Clinical Motor Physiology Laboratory, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Arch Neurol 61:858-61. 2004
    ..Reaction time (RT) and movement time (MT) analysis, validated quantitative measures of premovement neural processing and motor execution, can be used as objective physiological markers of motor performance in PD...
  41. pmc Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice
    Rebecca Banerjee
    Department of Pharmacology and Experimental Neuroscience, Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
    PLoS ONE 3:e2740. 2008
    ..Thus, the role of T cell immunity in disease was investigated in human G93A superoxide dismutase 1 (SOD1) transgenic (Tg) mice and subsequently in ALS patients...
  42. ncbi Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum?
    Michael J Strong
    Department of Clinical Neurological Sciences, The University of Western Ontario, The Cell Biology Research Group, Roberts Research Institute, London, Ontario, Canada
    Amyotroph Lateral Scler Other Motor Neuron Disord 6:8-16. 2005
    ..Only through the development and application of exacting clinical diagnostic criteria to epidemiological studies, along with greater numbers of post-mortem examinations, however, will these questions be answered fully...
  43. ncbi Olfactory ensheathing glia injections in Beijing: misleading patients with ALS
    Sheena Chew
    Department of Neurology, Eleanor and Lou Gehrig MDA ALS Research Center, Columbia University, New York, NY 10032, USA
    Amyotroph Lateral Scler 8:314-6. 2007
    ..Clinics that give experimental and potentially harmful treatments outside the construct of well-designed clinical trials put patients at risk and do a disservice to the ALS community...
  44. ncbi Lou Gehrig, rawhide, and 1938
    Melissa Lewis
    Eleanor and Lou Gehrig MDA ALS Research Center, Department of Neurology, Columbia University, New York, NY, USA
    Neurology 68:615-8. 2007
    ..A photograph of Gehrig from October 1939 showed hand atrophy. Photos from the spring of 1938 showed normal hand muscles and leg function, implying that visible signs first appeared after May 1938...

Research Grants6

  1. Phase III Trial of Minocycline in ALS:I-Clinical Center
    Paul Gordon; Fiscal Year: 2006
    ..P.I. Dr. Robert Miller). ..
  2. Phase III Trial of Minocycline in ALS:I-Clinical Center
    Paul Gordon; Fiscal Year: 2007
    ..P.I. Dr. Robert Miller). ..